[1/2] The exterior of Johnson and Johnson's subsidiary Janssen Vaccines in Leiden, Netherlands, March 9, 2021. REUTERS/Piroschka van de Wouw Acquire Licensing RightsAMSTERDAM, Aug 23 (Reuters) - Johnson & Johnson's (JNJ.N) Janssen division, which helped to develop its single-dose COVID-19 vaccine, will close much of its vaccine research and development operations in the Netherlands, newspaper De Telegraaf reported. In an emailed response on Wednesday, Johnson & Johnson confirmed plans to exit some of its vaccine research and development programmes, which it said it had initially disclosed in its 2023 second-quarter results. De Telegraaf reported that 2,500 people worked at Janssen in the Netherlands, a quarter of which were in the section specialising in infectious diseases and vaccines. J&J's relatively large Dutch vaccine operation stems in part from its $2.1 billion acquisition in 2011 of vaccine maker Crucell.

---

Persons: Johnson, de Wouw, Janssen, De Telegraaf, J, Charlotte Van Campenhout, Toby Sterling, David Goodman, David Evans Organizations: Janssen Vaccines, REUTERS, Rights, Thomson Locations: Leiden, Netherlands